All In Biotech

Drug Trial Radar · NCT06394492

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

May 10, 2024

Primary completion

May 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • SHR-A1921Drug

    SHR-A1921 dose 1

  • DoxorubicinDrug

    Doxorubicin dose 2

  • PaclitaxelDrug

    Paclitaxel dose 3

  • TopotecanDrug

    Topotecan dose 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1Time frame: Screening up to study completion, an average of 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.